This trial is testing whether delivering more radiation over a shorter time period is more effective in treating cervical or endometrial cancer with fewer side effects.
- Cervical Cancer
- Endometrial Cancer
3 Primary · 10 Secondary · Reporting Duration: At week 3 and 1 year
1 Treatment Group
Treatment (hypo-fractionated radiotherapy)
1 of 1
64 Total Participants · 1 Treatment Group
Primary Treatment: Hypofractionated Radiation Therapy · No Placebo Group · N/A
Who is running the clinical trial?
Age 18+ · Female Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any openings for volunteers to join this research at present?
"According to the data posted on clinicaltrials.gov, this trial is still enlisting participants. The initial posting occurred on 11th November 2021 and was last revised on 1st March 2022." - Anonymous Online Contributor
What is the sampling size of this research project?
"Affirmative. According to the clinicaltrials.gov website, enrollment is open for this experiment which was initially advertised on November 11th 2021 and last modified on March 1st 2022. 64 volunteers must be recruited from a single medical center." - Anonymous Online Contributor
What is the primary objective of this clinical trial?
"The primary purpose of this trial, which will be conducted over Baseline to week 3 of pelvic radiotherapy, is to assess the efficacy of hypofractionated radiotherapy. Auxiliary objectives include assessing financial toxicity with a Comprehensive Score for Financial Toxicity, making use of Decision Regret Scale and looking at changes in Functional Assessment of Cancer Therapy-Cervix (all using 90% confidence intervals)." - Anonymous Online Contributor